中国临床药理学杂志2017，Vol.33Issue(13)：1188-1190,3.DOI:10.13699/j.cnki.1001-6821.2017.13.006
紫杉醇注射液联合奈达铂注射剂治疗晚期复发转移性宫颈癌的临床研究
Clinical trial of paclitaxel injection combined with nedaplatin injection in the treatment of patients with metastatic cervical cancer
摘要
Abstract
Objective To observe the clinical efficacy and safety of paclitaxel injection combined with nedaplatin injection in the treatment of advanced recurrent metastatic cervical cancer.Methods Forty-five patients with advanced recurrent metastatic cervical cancer were given intravenous infusion of 150 mg · m-2 paclitaxel,day 1 + 80 mg · m-2 nedaplatin,day 1.The curative effect,adverse drug reactions and prognosis were observed.Results After treatment,complete remission was 3 cases (6.67％),partial response was 21 cases (46.67％),stable disease was 10 cases (22.22％),progress disease was 11 cases (24.44％),objective response rate was 53.33％ (24/45 cases).The clinical efficacy of time since the last chemotherapy (＞ 12 months or ≤ 12 months) were 20.00％ (3/15 cases) and 80.95％ (17/21 cases) with significant difference (P ＜ 0.05).Median overall survival time was 13.90 months with 42 patients died.Cox single regression showed that there were no significant differences between patients in terms of chemotherapy or not,and median overall survival rate since the last chemotherapy (P ＞0.05).The adverse drug reactions were based on bone marrow suppression,gastrointestinal reactions,fatigue and peripheral nerve sensory abnormalities.Conclusion Paclitaxel injection combined with nedaplatin injection has a definitive clinical efficacy and safety for the treatment of metastatic cervical cancer with good prognosis.关键词
紫杉醇注射液/奈达铂注射剂/宫颈癌/安全性Key words
paclitaxel injection/nedaplatin injection/cervical cancer/safety分类
医药卫生引用本文复制引用
张冬丽,李艳云,田君,张红霞,王社莲,孙桂霞..紫杉醇注射液联合奈达铂注射剂治疗晚期复发转移性宫颈癌的临床研究[J].中国临床药理学杂志,2017,33(13):1188-1190,3.基金项目
河南省高等学校重点科研基金资助项目(17A320023) （17A320023）
开封市社会发展科技公关计划基金资助项目(1603053) （1603053）
